Tuesday, June 02, 2015 4:48:01 PM
I did research on Fidelity site and found a report of -.40 for the PE ratio. Their debt is .8 of their capitalization. So, as far as I can see, VIVEVE is still in beginning stage of the growth cycle. That is, research, production, and distribution. Apparently, they have a multitude of backers. The perfect formula for going deeply into debt and diluting the stock to pay off the insiders.
They just entered the South Korean market. Let's hope they can sell this contraption and appease their female customers, which is the research outcome.
I am confident that the management is dedicated and experienced.
Sentiment: Strong Buy
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM